CRH (CRH) H2 2013 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2013 earnings summary
19 Nov, 2026Executive summary
2013 sales were flat at €18bn; EBITDA of €1.48bn came slightly ahead of guidance, and EPS was just under €0.60.
2013 was described as the earnings trough; H2 revenue and EBITDA improved, with stabilization signs in Europe and stronger momentum in the Americas.
Portfolio review targets higher returns through focused capital allocation and reallocation, with a goal of restoring group returns to historical peaks of 12%–13%.
Financial highlights
EBITDA movement reflected €197m of cost savings, ahead of the prior €125m expectation; H2 trading was €20m ahead YoY after a €105m shortfall at June.
Operating cash generation was just under €750m; CapEx was €500m, and working capital closed at 11.2% of sales.
Cash balance was €2.5bn and committed facilities almost €2bn, for €4.5bn total liquidity; net debt was below €3bn, about 2x EBITDA.
A €755m impairment charge related to identified exit businesses; 2012 comparisons included €61m of pension-curtailment and CO₂ gains versus €32m in 2013.
Outlook and guidance
2014 expected to bring growth at a moderate pace; U.S. residential recovery to broaden into non-residential, while infrastructure was expected broadly flat.
Europe expected to show positive momentum, with early-2014 stabilization; country outlook ranged from slightly up in Switzerland, Belgium, Germany and Poland to flat in the Netherlands and Finland.
2014 CapEx expected near €500m and finance costs near €300m; expected tax rate 22%–24%.
Cost savings target for 2012–15 was raised to €535m from €450m; 2014–15 targets remained unchanged.
Latest events from CRH
- Strong organic profit growth and cash generation cut year-end net debt below 3x EBITDA.CRH
H2 2015 - Strong growth and cash generation cut leverage to 1.7x while supporting further growth.CRH
H2 2016 - €3.3bn EBITDA, stronger margins and returns, and major acquisitions positioned for further growth.CRH
H2 2017 - U.S. momentum and cost actions supported 2013 progress as net debt fell EUR 519m.CRH
H2 2012 - EBITDA rose 11% in 2014; 2015 priorities were growth, integration and debt reduction.CRH
H2 2014 - Sales rose 5% and EBITDA reached €1.66bn as margins proved resilient.CRH
H2 2011 - Cash discipline and cost savings steadied results as markets began to stabilize.CRH
H2 2010 - Q3 EBITDA held near prior year; FY26 guidance is $7.8B–$8.0B amid cost and residential headwinds.CRH
Q3 2026 - Q2 2026 saw strong growth, margin gains, and the Arcosa deal, supporting a positive outlook.CRH
Q2 2026